Agenda

Business Highlights

- Product Pipeline Update
- Commercialization
- Financial Review
- Appendix
Business highlights in 2021

Laparoscopic
- Toumai® 1st received NMPA approval in Jan 2022
- Toumai® 2nd completed enrollment of registrational clinical trial covering indications including gynecologic, thoracic and general surgery
- Toumai® single-arm completed first human clinical trial (FIM) of single port laparoscopy cholecystectomy completed in Dec 2021
- DFVision® received NMPA approval

Natural orifice
- Trans-bronchial surgical robot completed the FIM clinical trial in Mar 2022

Orthopedic
- Honghu submitted NMPA registration application for TKA in Jul 2021
- Submitted FDA registration application for TKA in Dec 2021

Panvascular
- R-ONE® commenced the enrollment of the NMPA registrational clinical in Nov 2021

Percutaneous
- Mona LisaTM commenced the enrollment of the NMPA registrational clinical in Nov 2021, with most trial surgeries completed as of reporting date

Commercialization

- Training:
  - Established 10+ training centers nationwide in 2021, mainly through collaboration with reputable hospitals
  - Provided trainings for nearly 300 surgeons
  - Toumai® Mobile Platform launched in Dec 2021

- Sales:
  - DFVision® started to contribute sales from Nov 2021

- Team:
  - A well-trained and experienced marketing team, providing hospitals with training, maintenance for robots, equipment adjustment and other comprehensive services

R&D

- Five foundation technologies: robot ontology, control algorithms, electrical engineering, image-based navigation and precision imaging
- Largest surgical robot R&D team in China
- 4 R&D centers – Shanghai, Shenzhen, Singapore and Boston
- 500+ patents granted or in application globally - No.1 in domestic industry

IPO

- Successful listed on the Main Board of HKEX on 2 Nov 2021 - First China surgical robot company listed on HKEX
- Raised USD231mm in HK IPO
- Included in Hang Seng Composite Index in Mar 2022

Note: 1 as of Dec 31, 2021
Only surgical robot company world-wide covering all 5 major and fast-growing surgical specialties

<table>
<thead>
<tr>
<th>China Market Opportunities (2026E)</th>
<th>US$2,315mm (20A-26E CAGR: 39%)</th>
<th>US$451mm (20A-26E CAGR: 48%)</th>
<th>US$180mm (22E¹-26E CAGR: 151%)</th>
<th>US$129mm (23E¹-26E CAGR: 161%)</th>
<th>US$264mm (20A-26E CAGR: 53%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major Global / Domestic Listed Peers²</td>
<td>Overview of Surgical Specialties Coverage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intuitive Surgical</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>CMR Surgical</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stryker / Mako</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medtronic / Mazor</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zimmer Biomet / Rosa</td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Siemens</td>
<td></td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td></td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>WEGO (威高)</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TINAVI (天智航)</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

Source: Frost & Sullivan analysis
Notes: ¹ Expect to have first commercialized surgical robot product in that year; ² Refers to peers with market cap of over US$1bn
Laparoscopic surgical robot
Flagship product – Toumai® Laparoscopic Surgical Robot

Toumai® 1st Generation

- Patient-side Cart
- 3DHD Vision System
- Surgeon’s Console
- Instruments and Accessories
- Four robotic arms compatible with highly complex surgeries
- Reduce surgical wounds, incidences of post-surgical complications for faster recovery
- Robotic arms with high degrees of freedom
- Tremor-filtered instrument movement
- Immersive 3DHD visualization
- Reduced surgeon fatigue through natural hand-eye alignment

Toumai® 1st Generation

- Completed the design for Toumai® 1st Generation
- May 2018
- Admitted to NMPA Green Path
- Completed the First human clinical trial (FIM) of single port laparoscopy cholecystectomy
- Dec 2021
- The first Chinese-developed surgical robot that had completed registrational clinical trial for complex urologic surgeries
- Jan 2018
- Admitted to NMPA Green Path
- The first Chinese-developed surgical robot that had completed registrational clinical trial for complex urologic surgeries
- May 2021
- Obtained NMPA approval
- Jan 2022

Toumai® 2nd Generation

- Initiated patient enrollment for registrational clinical trial in gynecologic, thoracic and general surgeries
- Oct 2021
- Completed enrollment for multidisciplinary, multicenter-registered clinical trails
- Jan 2022
- Completed the First human clinical trial (FIM) of single port laparoscopy cholecystectomy
- Dec 2021

Toumai® Single-arm

First of its kind completed with a Chinese-developed laparoscopic surgical robot

- RALRP1 (removal of the entire prostate)
- Dongfeng Hospital in Shanghai (Nov 2019)
- Zhejiang Provincial People’s Hospital in Hangzhou (Dec 2020)

- RAPN2
- Zhongshan Hospital in Shanghai (Dec 2020)
- Zhongshan Hospital in Shanghai (Dec 2020)

- Extraperitoneal RALRP1
- Zhongshan Hospital in Shanghai (Dec 2020)

- RAPN2 adopting a retroperitoneal approach
- Zhejiang Provincial People’s Hospital in Hangzhou (Dec 2020)

- Single-port RAPN2

Note: 1 Robot-assisted laparoscopic radical prostatectomy; 2 Robot-assisted partial nephrectomy
Laparoscopic surgical robot (cont’d)
Toumai® 2nd generation – clinical trial milestone surgeries

First and only domestic laparoscopic surgical robot to conduct clinical trial on all 4 indications

2nd globally & 1st domestic laparoscopic surgical robot to accomplish all types of complex surgeries

Full application of clinical specialties in thoracic, laparoscopic and pelvic cavity surgeries

Clinical trial centers coverage

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 Oct 2021</td>
<td>Completed first patient enrolment of the multi-specialty, multi-center clinical study</td>
</tr>
<tr>
<td>26 Oct 2021</td>
<td>Completed a Radical resection of distal gastric cancer(远端胃癌根治术), marked important progress made in clinical application of general surgery</td>
</tr>
<tr>
<td>18 Nov 2021</td>
<td>First domestic four-arm robot assisted total hysterectomy and bilateral adnexectomy (全子宫及附件切除术)</td>
</tr>
<tr>
<td>14 Dec 2021</td>
<td>First radical gastrectomy for gastric cancer(胃癌根治术) assisted by Toumai in Southeast China</td>
</tr>
<tr>
<td>29 Dec 2021</td>
<td>First domestic robot assisted Cholecystectomy and Choledocholithotomy (联合胆道镜胆囊切除及胆总管取石术)</td>
</tr>
<tr>
<td>22 Jan 2022</td>
<td>Completed patient enrollment for gynecologic, thoracic, general surgery – completed patient enrollment for Toumai® 2nd generation</td>
</tr>
<tr>
<td>25 Oct 2021</td>
<td>Completed a Right lung lower lobe resection(右肺下叶切除术) - important progress in clinical application of thoracic surgery</td>
</tr>
<tr>
<td>11 Nov 2021</td>
<td>First domestic four-arm robot assisted radical resection of sigmoid colon cancer(乙状结肠癌根治术) in Jiangxi province</td>
</tr>
<tr>
<td>26 Nov 2021</td>
<td>First domestic robot assisted Sleeve Gastrectomy Gastric Volume Reduction Surgery(袖状胃切除胃减容手术) in East China</td>
</tr>
<tr>
<td>03 Dec 2021</td>
<td>First domestic robot assisted gynecological operation in East China - total hysterectomy with double adnexectomy (全子宫双附件切除术)</td>
</tr>
<tr>
<td>9 Dec 2021</td>
<td>First domestic robot assisted Radical resection of right colon cancer (右半结肠癌根治术) in East China</td>
</tr>
<tr>
<td>28 Dec 2021</td>
<td>First domestic robot assisted clinical trial in gynecologic surgery in Northeast China - total hysterectomy (全子宫切除术)</td>
</tr>
</tbody>
</table>
Laparoscopic surgical robot (cont’d)
Flagship product – DFVision® 3D Electronic Laparoscope

- The first Chinese-developed 3D electronic laparoscope admitted to the NMPA Green Path in Apr 2019
- The first surgery completed with Chinese-developed 3D electronic laparoscope in China in Oct 2019
- DFVision® - I received NMPA approval in Jun 2021
- DFVision® - II at prototype testing stage, will submit NMPA application in 2022E

Light weight
- DFVision®’s dual objective lenses are placed at the tip of the borescope
- Easier for surgeons to manipulate precisely, particularly in small surgical fields

3D Stereo visualization
- The natural depth of field allows the surgeon to have intuitive observation

HD High-definition, real-time image transmission
- Strong image transmission and processing capabilities
- High magnification feature enables surgeons to zoom in the view smoothly, observe minute blood vessels clearly and operate with greater precision

Commercialization Progress

- Kicked off marketing campaigns for DFVision® in 2H 2021
- Commercial launch with sales contribution since 4Q 2021 and promote product awareness among target hospitals and surgeons
- To help surgeons gain familiarity with the product and collect feedbacks
Orthopedic surgical robot
Flagship product – Honghu Orthopedic Surgical Robot

The only Chinese-developed joint replacement surgical robot with a self-developed robotic arm. Expected to be the first Chinese-developed surgical robot to obtain FDA approval.

- 3D image-based preoperative plan to define the optimal implant size according to the patient’s anatomy
- Significantly decreased radiation exposure and improved cost-efficiency
- Precise bone cutting and implant placement to reduce surgical complications and facilitate patients’ recovery
- Innovative and novel navigation and positioning to optimize postoperative outcome

Timeline:

- **May 2020**: Entered the NMPA Green Path in May 2020
- **Sep 2020**: Honghu commenced a registrational clinical trial in China for TKA with ~100 patients enrolled in Sep 2020
- **Jan 2021**: Patient enrollment for Honghu’s registrational clinical trial for TKA completed in Jan 2021
- **Jul 2021**: Registration application submitted NMPA registration application for TKA in Jul 2021
- **Dec 2021**: Registration application submitted FDA registration application for TKA in Dec 2021
- **Next step**: Indication expansion

- To commence a clinical trial for THA in China by the end of 2022
Natural Orifice Surgical Robot

Robot-assisted natural orifice surgery

Surgery application

- Natural orifice surgical robots refer to robots that deliver surgical instruments to the target anatomy through natural pathways of the human body and control them for diagnosis or surgery.
- Natural orifice surgical robots are applied in natural orifice transluminal laparoscopic surgeries, such as:
  - Bronchoscopy (examination of the lungs)
  - Colonoscopy (examination of the bowel)
  - Gastroscopy (examination of the stomach)

Competitive landscape

- Globally there are only 3 FDA approved natural orifice surgical robots.
- In China, there is no NMPA approved natural orifice surgical robots.

Product

Features / Technology

- Leverage the power of flexible robotics which uses a camera and tools to enter the lungs through their natural airways.
- Precisely guide a biopsy instrument to those hard-to-reach nodules.

Indication application

Trans-bronchial diagnosis and treatment

Clinical status

- Completed FIM clinical trial in Mar 2022 – First trial surgery completed by domestic trans-bronchial surgical robot.
- Registrational clinical trial (2023).
- NMPA registration application (2024).
Panvascular Surgical Robot

**R-ONE® Vascular Interventional Surgical Robot**

**Robot-assisted panvascular surgery**

**Surgery application**
- Panvascular surgical robots are used to treat diseases of the vasculature or related organs in the heart, the brain or the peripheral vascular system
- Panvascular robots not only move surgeons outside the operating room, but more importantly achieve better precision and controllability of operations

**Competitive landscape**
- Globally there are only 4 panvascular surgical robots approved by FDA or obtained CE Marking
- In China, there is no NMPA approved panvascular surgical robots

**Features / Technology**
- Designed to operate with precision and perform specific movements
- Facilitate and enhance the interventional procedures performed on the patient

**Indication application**
- Coronary angioplasty

**Clinical status**
- Commenced the enrollment of the NMPA registrational clinical trial in Nov 2021 - marking a field of vascular milestone of the Company in the intervention
- Expect to submit NMPA registration application in 2022E

---

**Note:**
1. Transcatheter aortic valve replacement

**Product**
- R-ONE® Vascular Interventional Surgical Robot ("R-ONE®")

**CE Marking**
Percutaneous Surgical Robot
Mona Lisa Robotic Transperineal Prostate Biopsy System

Robot-assisted percutaneous surgeries

Surgery application

- Percutaneous surgical robots are indicated for percutaneous surgeries, which are primarily procedures to collect tissue samples for diagnostic purposes, such as the detection of early-stage lung cancer, breast cancer and prostate cancer.

Competitive landscape

- Globally, there are only 4 percutaneous surgical robots approved by FDA or obtained CE Marking.
- In China, there are only 2 NMPA approved percutaneous surgical robots.

Features / Technology

- Real-time 2D ultrasound images displayed on the monitor during the biopsy procedure.
- The surgeon manually inserts the needle into the prostate to collect the biopsy cores.

Indication application

Transperineal prostate biopsy¹
Expect to cooperate with Toumai®, providing integrated solutions in urology.

Clinical status

- China:
  - Completed most trial surgeries of the NMPA registrational clinical trial as of the reporting date – 1st robotic assisted prostate puncture biopsy clinical trial in China.
  - Expect to submit NMPA registration application in 2022E.

Note: ¹ A diagnostic procedure in which the surgeon passes the biopsy needle through the perineal skin and into the prostate.
Cutting-edge technology

Remote surgery
- 5G dedicated network, low delay operation
- Multilevel safety mechanism for remote surgery to ensure the safety
- Real-time communication by multi-patry
- Remote control, core parameter return

Automatic operation
- Intelligence image diagnosis – Automatic cutting, diagnosis and positioning
- Intelligence surgery planning – Automatic learning to avoid key autonomy structure and establish safe & efficient surgery planning
- Automatic precision treatment – precision control of equipment to drive surgery operation and completed automatic surgery closed loop

- Toumai®
  - Completed the first 5G Remote animal experiment at three locations
- Honghu
  - Completed the first 5G Remote Joint Replacement Surgery

- Successfully conducted animal testing using unmanned, fully automated surgical platform Madame Curie™ in Dec 2021
Agenda

Business Highlights

Product Pipeline Update

Commercialization

Financial Review

Appendix
Experienced team and well-planned strategies for commercialization

- **Dedicated specialized team**
  - 100+ professionals, covering sales and marketing, surgeon training, clinical support and after-sales services
  - Specialized commercialization team with extensive experience of the sales of da Vinci surgical robots in China

- **Surgeon training and clinical support**
  - Target surgeon education and training to increase the adoption rate of our surgical robots
  - Provide tailored solutions based on surgeons’ feedback
  - Co-develop next-generation surgical robots

- **Patient education**
  - Increase awareness of surgical robots among patients
    - Mass media promotion
    - Clinical performance
    - Potential medical insurance coverage

- **After-sales service**
  - One-stop solutions covering multiple surgical departments with robot-assisted surgery needs
  - Global service network comprising surgical robot trainers, clinical support personnel and after-sales service engineers

- **Academic promotion / surgeon training and clinical support**
  - Target surgeon education and training to increase the adoption rate of our surgical robots
  - Provide tailored solutions based on surgeons’ feedback
  - Co-develop next-generation surgical robots

- **Sustainable after-sales service for hospital**
  - One-stop solutions covering multiple surgical departments with robot-assisted surgery needs
  - Global service network comprising surgical robot trainers, clinical support personnel and after-sales service engineers
Strong industrial operation capabilities for surgical robots

- **Largest** surgical robot R&D team in China, covering **8 major functions**
  - Electrical engineering
  - Software development
  - Testing
  - Vision imaging development
  - Algorithm development
  - Mechanical engineering
  - Quality management system in accordance with ISO13485 standard covering every aspect of operations

- **Most of** R&D team members hold a master’s or higher degree
- **Globally-located R&D centers** in Shanghai, Shenzhen, Boston and Singapore
- Collaboration with **top-tier institutions**
- **500+ patents** granted or in application globally

- **Standard Setting**
  - **Global**
  - **In-house**

- **Quality control**
  - Design & Development
  - Procurement
  - Registration
  - Services
  - Promotion
  - Manufacturing

- **R&D**
  - Completed 2 registrational clinical trials for Toumai® and Honghu concurrently
  - Completed enrollment of Toumai®-II registrational clinical trials for 3 indications in ~3 months
  - Collaboration with top-tier hospitals

- **Supply chain**
  - Orthopedic surgical robot manufacturing facility
  - Laparoscopic surgical robot manufacturing facility
  - Establishing a second laparoscopic surgical robot manufacturing facility in Shanghai
  - Over 100 selected suppliers from 13 countries

- **Clinical trial & registration**
  - In-house manufacturing and supply chain team

Most of R&D team members hold a master’s or higher degree. Globally-located R&D centers in Shanghai, Shenzhen, Boston and Singapore. Collaboration with top-tier institutions. 500+ patents granted or in application globally.
Clear global vision and established footprint

Global expansion starting form R&D

Potential product launch overseas and global supply chain management

Strategic investment and collaborations with global partners to co-develop next-generation product

159 patents granted, 344 patents pending application approval globally\(^2\)

---

**Note:** 1 Including shares held by MicroPort MedBot and ESOP \(^1\) As of Dec 31, 2021

---

1. France-based company providing robotic solutions to treat vascular diseases
   China JV shareholding: 51%

2. Singapore-based company which has developed automated needle targeting robotics used in percutaneous biopsy
   China JV shareholding: 61%

3. Singapore-based company dedicated to developing minimally invasive robotic healthcare solutions
   China JV shareholding: 70%

---

- **R&D center**
- **Patent registration**
- **Global partners**
Agenda

Business Highlights

Product Pipeline Update

Commercialization

Financial Review

Appendix
Successful product launch, funding future and adequate cash balance

Successful product launch
Primarily from the sales of DFVision since its approval by NMPA in Jun 21

Revenue
(RMB million)

2020 2021
2.2

Operating performance
(RMB million)

Net loss of 584.5m with oper. performance loss 452.8m, YoY 134%, around 70% of which invested in R&D

Funding future

2020 2021

15.8 40.5
193.5 452.8
43%
134%

Adequate cash for opportunities
1,940.8m at 21YE, YoY 30%
- Net IPO and over-allotment +1,375m
- Strategic partnership investment (263m)

Cash Balance
(RMB million)

2020 2021

1,497.3 1,940.8
30%

SBP  Listing fee
Investment on future – Operating Expenses

**Invest for sustainable growth**

**R&D Cost**
- (RMB million)
- **2020**: 135.4
- **2021**: 336.4
- **190% YoY increase**

- **R&D 392.6m**, +257m / 190% YoY, on-going and new projects
  - Personnel costs +130m, incl. SBP +47m
  - Consumable +67m

**Prepare for sales ramp-up**

**S&M Expenses**
- (RMB million)
- **2020**: 2.7
- **2021**: 66.5
- **2841% YoY increase**

- **S&M 79.2m**, +77m / 2841% YOY
  - The expansion of specialized commercial team
  - Expenses for training surgeons

**Support overall business growth**

**Administrative Expenses**
- (RMB million)
- **2020**: 20.8
- **2021**: 85.2
- **107.5M**, increased by 300% YOY

- Increase of mgt & admin staff costs
- Consulting and service fee
- Office rental expenses
Research and Development Cost

**Fund pipeline products**

- Laparoscopic: 58%
- Orthopedic: 19%
- Others: 22%

Total: 392.6m

**Invest in foundation technologies**

- Costs of materials and consumables: 28%
- Others: 23%
- Staff Costs: 48%

Total: 392.6m

- **Laparoscopic:** Toumai®1st received NMPA approval in Jan 22; Toumai®2nd completed enrollment of registration clinical trial; Single-arm completed FIM
- **Orthopedic:** Submitted NMPA & FDA registration application for TKA
- **Others:** Natural orifice and other products
- **Staff Costs** – the largest surgical robot R&D team in China
- **Cost of materials and consumables,** 4 R&D centers, foundation tech platform and cutting-edge technology progression
Agenda

- Business Highlights
- Product Pipeline Update
- Commercialization
- Financial Review
- Appendix
## Financial Statement – P&L

<table>
<thead>
<tr>
<th>Unit: RMB'000</th>
<th>2021</th>
<th>2020</th>
<th>Var.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>2,150</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Cost of sales</td>
<td>(1,231)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Gross profit</td>
<td>919</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Other net income</td>
<td>24,675</td>
<td>9,777</td>
<td>152%</td>
</tr>
<tr>
<td>Selling and marketing expenses</td>
<td>(79,188)</td>
<td>(2,693)</td>
<td>2841%</td>
</tr>
<tr>
<td>Administrative expenses</td>
<td>(107,477)</td>
<td>(26,884)</td>
<td>300%</td>
</tr>
<tr>
<td>Research and development costs</td>
<td>(392,649)</td>
<td>(135,378)</td>
<td>190%</td>
</tr>
<tr>
<td>Net gain/(loss) on financial instruments carried at fair value through profit or loss (FVPL)</td>
<td>45,523</td>
<td>(3,250)</td>
<td>-1501%</td>
</tr>
<tr>
<td>Other operating costs</td>
<td>(43,498)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Loss from operations</td>
<td>(551,695)</td>
<td>(158,428)</td>
<td>248%</td>
</tr>
<tr>
<td>Finance costs</td>
<td>(5,435)</td>
<td>(49,187)</td>
<td>-89%</td>
</tr>
<tr>
<td>Share of losses of equity-accounted investees</td>
<td>(27,377)</td>
<td>(1,675)</td>
<td>1534%</td>
</tr>
<tr>
<td>Loss before taxation</td>
<td>(584,507)</td>
<td>(209,290)</td>
<td>179%</td>
</tr>
<tr>
<td>Income tax</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Loss for the year</td>
<td>(584,507)</td>
<td>(209,290)</td>
<td>179%</td>
</tr>
<tr>
<td>Attributable to:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Equity shareholders of the Company</td>
<td>(582,921)</td>
<td>(208,874)</td>
<td>179%</td>
</tr>
<tr>
<td>Non-controlling interests</td>
<td>(1,586)</td>
<td>(416)</td>
<td>281%</td>
</tr>
<tr>
<td>Loss for the year</td>
<td>(584,507)</td>
<td>(209,290)</td>
<td>179%</td>
</tr>
<tr>
<td>Loss per share (RMB)</td>
<td>Basic and diluted (RMB)</td>
<td>(0.63)</td>
<td>(0.27)</td>
</tr>
</tbody>
</table>
## Financial Statement – Balance Sheet

### Non-current assets

<table>
<thead>
<tr>
<th></th>
<th>31 Dec 2021</th>
<th>31 Dec 2020</th>
<th>Var.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Property, plant and equipment</td>
<td>361,000</td>
<td>38,710</td>
<td>833%</td>
</tr>
<tr>
<td>Intangible assets</td>
<td>3,074</td>
<td>565</td>
<td>444%</td>
</tr>
<tr>
<td>Goodwill</td>
<td>1,482</td>
<td>1,482</td>
<td>0%</td>
</tr>
<tr>
<td>Equity-accounted investees</td>
<td>123,537</td>
<td>85,430</td>
<td>45%</td>
</tr>
<tr>
<td>Financial assets measured at FVPL</td>
<td>136,586</td>
<td>38,366</td>
<td>256%</td>
</tr>
<tr>
<td>Derivative financial instruments</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Other non-current assets</td>
<td>71,979</td>
<td>12,075</td>
<td>496%</td>
</tr>
<tr>
<td><strong>Total Non-current assets</strong></td>
<td><strong>697,658</strong></td>
<td><strong>189,304</strong></td>
<td><strong>269%</strong></td>
</tr>
</tbody>
</table>

### Current assets

<table>
<thead>
<tr>
<th></th>
<th>31 Dec 2021</th>
<th>31 Dec 2020</th>
<th>Var.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derivative financial assets</td>
<td>8,958</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Inventories</td>
<td>109,881</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Trade and other receivables</td>
<td>24,955</td>
<td>16,742</td>
<td>49%</td>
</tr>
<tr>
<td>Pledged deposits</td>
<td>9,607</td>
<td>982</td>
<td>878%</td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>1,940,825</td>
<td>1,497,326</td>
<td>30%</td>
</tr>
<tr>
<td><strong>Total Current assets</strong></td>
<td><strong>2,094,226</strong></td>
<td><strong>1,515,050</strong></td>
<td><strong>38%</strong></td>
</tr>
</tbody>
</table>

### Current liabilities

<table>
<thead>
<tr>
<th></th>
<th>31 Dec 2021</th>
<th>31 Dec 2020</th>
<th>Var.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade and other payables</td>
<td>181,510</td>
<td>221,620</td>
<td>-18%</td>
</tr>
<tr>
<td>Provisions</td>
<td>96</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lease liabilities</td>
<td>52,863</td>
<td>7,288</td>
<td>625%</td>
</tr>
<tr>
<td><strong>Total Current liabilities</strong></td>
<td><strong>234,469</strong></td>
<td><strong>228,908</strong></td>
<td><strong>2%</strong></td>
</tr>
</tbody>
</table>

### Non-current liabilities

<table>
<thead>
<tr>
<th></th>
<th>31 Dec 2021</th>
<th>31 Dec 2020</th>
<th>Var.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contract liabilities</td>
<td>102</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Provisions</td>
<td>397</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lease liabilities</td>
<td>151,813</td>
<td>11,593</td>
<td>1210%</td>
</tr>
<tr>
<td>Deferred income</td>
<td>14,951</td>
<td>22,401</td>
<td>-33%</td>
</tr>
<tr>
<td><strong>Total Non-current liabilities</strong></td>
<td><strong>167,263</strong></td>
<td><strong>33,994</strong></td>
<td><strong>392%</strong></td>
</tr>
</tbody>
</table>

### NET ASSETS

<table>
<thead>
<tr>
<th></th>
<th>31 Dec 2021</th>
<th>31 Dec 2020</th>
<th>Var.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NET ASSETS</strong></td>
<td><strong>2,390,152</strong></td>
<td><strong>1,441,452</strong></td>
<td><strong>66%</strong></td>
</tr>
</tbody>
</table>
Thanks!